Sigyn Therapeutics, Inc. Sigyn Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Sigyn Therapy
  • Therapeutic Opportunities
    • Overview
    • Sepsis
    • Virus-induced Cytokine Storm
    • Bacteria-induced Cytokine Storm
    • Acute Respiratory Distress Syndrome
    • Hepatic Encephalopathy
    • Bridge-To-Liver Transplant
  • News & Media
    • Press Releases
    • Presentations
    • Resources
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Resources
Jan 26, 2021 8:30am EST

Sigyn Therapeutics Appoints Eric Lynam as Head of Clinical Affairs

Jan 19, 2021 8:30am EST

Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview

Jan 12, 2021 8:30am EST

Sigyn Therapeutics (SIGY) CEO Note: Overcoming the Limitations of Previous Cytokine Storm Treatment Strategies

Jan 06, 2021 8:30am EST

Sigyn Therapeutics™ Reports Results of Pilot Study to Address Inflammatory CytoVesicles

Dec 01, 2020 8:45am EST

Sigyn Therapeutics™ Reports Simultaneous Clearance of Endotoxin and Inflammatory Cytokines From Human Blood Plasma

Nov 02, 2020 7:30am EST

Sigyn Therapeutics (SIGY) CEO Note: Rethinking the Treatment of Sepsis and Other Life-Threatening Inflammatory Conditions

Oct 19, 2020 4:30pm EDT

Sigyn Therapeutics Announces Completion of Merger with Reign Resources

Aug 26, 2020 4:30pm EDT

Reign Resources Corporation and Sigyn Therapeutics Announce Definitive Merger Agreement

RSS
© 2021 Sigyn Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap